Company Overview of ARCA biopharma, Inc.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
11080 CirclePoint Road
Westminster, CO 80020
Key Executives for ARCA biopharma, Inc.
Total Annual Compensation: $389.4K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $338.8K
Senior Vice President
Total Annual Compensation: $323.6K
Compensation as of Fiscal Year 2013.
ARCA biopharma, Inc. Key Developments
ARCA biopharma, Inc. Announces Health Canada Acceptance of GENETIC-AF Clinical Trial Application
Aug 18 14
ARCA biopharma, Inc. announced that the company's Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in the fourth quarter of 2014. ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the United States. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation. AF is a disorder in which the normally regular and coordinated contraction pattern of the heart's two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF) patients. GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients. ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial in approximately 200 patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.
ARCA biopharma, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM
Jun 13 14
ARCA biopharma, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.
ARCA biopharma, Inc. Elects Robert E. Conway as Chairman of the Board of Directors
Jun 9 14
ARCA biopharma, Inc. announced that Robert E. Conway has been elected Chairman of the company's Board of Directors. He serves on the Audit and Compensation Committees of the Board of Directors. Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. Mr. Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|